Zeposia (ozanimod) Letter of Medical Necessity
Zeposia (ozanimod) is an oral S1P receptor modulator used in relapsing MS and moderate-to-severe ulcerative colitis. Payers require a defined pre-treatment safety workup, and UC plans often require failure of conventional therapy or a preferred biologic. Most denials are reversible once baseline labs, ECG, and prior therapies are documented.
FDA-Approved Indications
- ● relapsing forms of multiple sclerosis
- ● moderately to severely active ulcerative colitis
Why Zeposia Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Baseline ECG, CBC, and liver function tests not documented
- 2. Varicella zoster virus antibody status or vaccination not documented
- 3. Step therapy: preferred MS disease-modifying therapy or UC biologic not tried first
- 4. Ophthalmologic exam not documented in patients with diabetes or uveitis history
- 5. Mayo score or MS relapse history not documented
What to Include in a Zeposia Letter of Medical Necessity
Document the diagnosis (MS with relapse history and MRI activity; UC with Mayo score and endoscopic findings), prior disease-modifying or conventional/biologic therapies with outcomes, baseline ECG, CBC, LFTs, VZV status, and ophthalmologic evaluation when indicated, plus the clinical rationale for an oral agent (e.g., needle aversion, infusion access barriers, or prior biologic failure).
Key clinical evidence to cite:
- ✓ SUNBEAM and RADIANCE Phase 3 trials — reduced annualized relapse rate vs interferon beta-1a in relapsing MS
- ✓ True North Phase 3 trial — clinical remission at induction and maintenance vs placebo in ulcerative colitis
- ✓ Oral once-daily dosing with no first-dose observation requirement for most patients after titration
Relevant guidelines:
- 📖 AAN 2018 Disease-Modifying Therapies for MS Guideline
- 📖 AGA 2024 Ulcerative Colitis Guideline
- 📖 ACG 2025 Ulcerative Colitis Guideline
Zeposia Prior Authorization Criteria
Standard criteria across major US payers for Zeposia. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: preferred MS disease-modifying therapy or UC biologic not tried first
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Zeposia
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Zeposia Prior Authorization FAQ
Why was my Zeposia prior authorization denied?
The most common denial reasons for Zeposia are: Baseline ECG, CBC, and liver function tests not documented; Varicella zoster virus antibody status or vaccination not documented; Step therapy: preferred MS disease-modifying therapy or UC biologic not tried first; Ophthalmologic exam not documented in patients with diabetes or uveitis history; Mayo score or MS relapse history not documented.
What should a Zeposia Letter of Medical Necessity include?
Document the diagnosis (MS with relapse history and MRI activity; UC with Mayo score and endoscopic findings), prior disease-modifying or conventional/biologic therapies with outcomes, baseline ECG, CBC, LFTs, VZV status, and ophthalmologic evaluation when indicated, plus the clinical rationale for an oral agent (e.g., needle aversion, infusion access barriers, or prior biologic failure).
Which payers cover Zeposia?
Zeposia is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.